Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 11/20 | 0.32 |
| ▸ | HNF4A | P41235 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 3/20 | 0.31 |
| ▸ | RARA | P10276 | 2/20 | 0.31 |
| ▸ | RXRB | P28702 | 2/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6913758 | 0.67 | MAOA (0.42) | RXRANR4A2RXRGRARARXRB | |
| SCHEMBL23446562 | 0.59 | RXRA (0.33) | RXRANR4A2 | |
| SCHEMBL15362735 | 0.58 | RXRA (0.36) | RXRAHNF4ANR4A2RXRGRARA | |
| SCHEMBL15362732 | 0.58 | CYP3A4 (0.37) | RXRARXRGRARARXRBRARB | |
| SCHEMBL11599145 | 0.58 | RXRA (0.42) | RXRARXRGRARARXRBRARB | |
| SCHEMBL2194526 | 0.58 | MAOB (0.46) | RXRARXRGRARA | |
| SCHEMBL15347722 | 0.58 | RXRA (0.60) | RXRAHNF4A | |
| Hydrochloric Acid SCHEMBL4219941 | 0.57 | RARA (0.33) | RXRARXRGRARARXRBRARB | |
| SCHEMBL5009416 | 0.56 | RXRA (0.41) | RXRARXRGRARARXRBRARB | |
| SCHEMBL6938404 | 0.56 | RARB (0.37) | RXRARXRGRARARXRBRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884820-B2 | 5,6,7,8-tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity | ALLERGAN, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| US-20040198825-A1 | 5,6,7,8-Tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity | ALLERGAN, INC. | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198825-A1 | 5,6,7,8-Tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity | TPO, TTR, FABP1 | RXRA 145/4885HNF4A 218/4885NR4A2 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.